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Abstract:  
Objective: Non-adherence to medication is present in ≥50% of patients with apparent 
treatment resistant hypertension. We examined the factors associated with non-adherence as 
detected by an LC-MS/MS based urine antihypertensive drug assay. 
Methods: All urine antihypertensive test results, carried out for uncontrolled hypertension 
(BP persistently >140/90 mmHg) between January 2015 and December 2016 at a single 
toxicology laboratory were analysed. Drugs detected were compared to the antihypertensive 
drugs prescribed. Patients were classified as adherent (all drugs detected), partially non-
adherent (≥1 prescribed drugs detected) or completely non-adherent (no drugs detected). 
Demographic and clinical parameters were compared between the adherent and non-adherent 
groups. Binary logistic regression analysis was performed to determine association between 
non-adherence and demographic and clinical factors.  
Results: Data on 300 patients from 9 hypertension centres across the UK were analysed. The 
median age was 59 years, 47% female, 71% Caucasian , median clinic BP was 176/95 mmHg 
and the median number of antihypertensive drugs prescribed was four. One hundred and 
sixty-six (55%) were non-adherent to prescribed medication with 20% of these being 
completely non-adherent. Non-adherence to antihypertensive medication was independently 
associated with younger age, female gender, number of antihypertensive drugs prescribed, 
total number of all medications prescribed (total pill burden) and prescription of a calcium 
channel blocker. 
Conclusion: This LC-MS/MS urine analysis-based study suggests the majority of patients 
with apparent treatment resistant hypertension are non-adherent to prescribed treatment. 
Factors that are associated with non-adherence, particularly pill burden, should be taken into 
account while treating these patients. 




Hypertension is one of the most important preventable causes of premature morbidity and 
mortality throughout the world. In 2017, globally, 10.4 million deaths and 218 million 
disability-adjusted life-years were attributable to high systolic blood pressure (BP) (2). 
Treatment resistant hypertension (TRH) is reportedly present in 5 to 30% of the total 
hypertensive population [1-6]. It is defined as office BP above 140/90 mmHg whilst on ≥3 
antihypertensive agents (one of which is usually a diuretic) at optimal or maximum tolerated 
doses [7-10].  
Patients with TRH are nearly 50% more likely to develop a cardiovascular event compared to 
those without [11]. One study estimated the risk of developing a fatal or non-fatal 
cardiovascular event over 5 years to be 2.4 fold higher in TRH compared with non-TRH [12]. 
Another analysis of 470,386 hypertensive patients from a single health care system showed 
that patients with TRH, compared to non-TRH, had increased risks of end stage kidney 
disease, ischaemic heart disease, heart failure, stroke, and mortality; with multivariable 
adjusted hazard ratios (95% confidence intervals) of 1.32 (1.27–1.37), 1.24 (1.20–1.28), 1.46 
(1.40–1.52), 1.14 (1.10–1.19), and 1.06 (1.03–1.08), respectively [13]. A post-hoc analysis of 
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) 
suggests that the risks of end stage kidney disease, cardiovascular events and mortality may 
be even higher than that found in the aforementioned study [14]. 
However, the true prevalence of TRH is difficult to determine because of apparent resistance 
due to white coat hypertension, poor adherence with prescribed medication, poor BP 
measurement techniques and inappropriate combination of treatment [15,16]. 
Notwithstanding the poor prognosis, as many as 53% of those with TRH are reported to be 
non-adherent to their prescribed medication [17]. Until recently, however, no simple, 
objective test of adherence existed, with commonly used indirect methods such as patient 
interview, prescription refill, and pill counts often inaccurate. Supervised administration of 
medications and monitoring of BP in directly observed therapy clinics are more accurate but 
costly in regards to bed/clinic usage and staff time, inconvenient and sometimes harmful to 
non-adherent patients [15,16].  
This need, coupled with the increased availability of more sensitive and robust mass 
spectrometry instrumentation, has led our group and others [17-19] to develop an objective 
test of adherence that is easy to administer, quick, inexpensive, and reliable, in order to 
identify patients with true resistance to antihypertensive drugs to optimize their treatment.  
The aims of this retrospective analysis were: (1) to determine the prevalence of non-
adherence in a cohort of apparent TRH using a well validated, liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) based urine drug assay (16); and (2) to ascertain the risk 
factors for non-adherence using routinely collected demographic and clinical parameters. 
Materials and Methods: 
 
Study Population – All patients with uncontrolled hypertension (clinic BP >140/90 mmHg on 
treatment) presenting to 9 hypertension centres across the U.K who had urine 
antihypertensive assay carried out in a single toxicology laboratory between January 2015 
and December 2016. The centres included were Heartlands Hospital, Birmingham; University 
Hospitals Coventry and Warwickshire NHS Trust, Coventry; University Hospitals Bristol 
NHS Foundation Trust, Bristol; Barts Heart Centre, London; Queen Elizabeth Hospital, 
Birmingham; University Hospitals of North Midlands NHS Trust, Stoke on Trent; Royal 
Wolverhampton NHS Trust, Wolverhampton; and the BHF Centre of Research Excellence, 
Edinburgh. All patients provided verbal consent for urine drug testing, but they had not been 
informed beforehand that that drug testing would be carried out at their clinic visit. 
Clinical Assessment – All patients had white coat hypertension excluded by ambulatory BP 
monitoring (by home BP in a few patients who did not tolerate or refused ambulatory 
monitoring), and secondary hypertension by appropriate investigations as per hospital 
protocol in each centre. Demographic details, clinic BP (taken using a validated BP monitor), 
eGFR, body weight, body mass index and list of all medications including antihypertensive 
medication were collected at clinic visits and recorded on urine analysis request forms for all 
patients. These data were used for analyses in this study. 
Drug Analysis – All urine samples received for urinary anti-hypertensive drug screening 
during the timeframe were analysed using the method outlined elsewhere (19). Briefly, 
standards or samples (50 µL) were manually pipetted into a 1.1 mL screw-topped conical 
glass vial. To this, 150 µL of an internal standard solution containing deuterated amlodipine, 
bisoprolol, doxazosin, hydrochlorothiazide and ramipril was added. Samples were vortex 
mixed for 10 sec and transferred to the LC-MS/MS instrument for analysis. For the period of 
audit, the LC-MS/MS assay detected the following drugs and metabolites: amlodipine, 
felodipine nifedipine, verapamil, diltiazem, lisinopril, perindopril, ramipril, enalapril, 
losartan, irbesartan, candesartan, indapamide, furosemide, bendroflumethiazide, 
hydrochlorothiazide, spironolactone metabolite, atenolol, labetalol, bisoprolol, metoprolol, 
doxazosin and moxonidine. 
Data Analysis - All urine antihypertensive test results performed for apparent TRH patients 
between January 2015 and December 2016 at Heartlands Hospital toxicology laboratory were 
included in the data set. Drugs detected were compared to the antihypertensive drugs 
prescribed. Patients were classified as adherent (all drugs detected) or non-adherent (≥1 
prescribed drug not detected). None of the subjects in the present cohort was on a drug that 
was not detectable by the assay. 
Statistical Package for the Social Sciences (SPSS) version 22 (IBM) was used for statistical 
analysis. Demographic and clinical data were compared across the two groups using a Mann-
Whitney U, for the continuous variables which were non-parametric). Pearson Chi-Square 
test was used for categorical variables. The parameters compared were age, gender, ethnicity, 
body weight, body mass index (BMI), estimated glomerular filtration rate (eGFR), clinic 
systolic and diastolic BP readings at the point of urine testing, total number of medications 
prescribed (total pill burden) and number of antihypertensive medications prescribed. Class 
of drugs prescribed (angiotensin-converting enzyme inhibitors [ACE-I], angiotensin II 
receptor antagonists [ARB], beta-blockers, calcium channel antagonists, diuretics and other 
antihypertensive medications) were also compared to adherence class.  
Binary logistic regression was used to generate prediction models for overall non-adherence 
(20). Adherence status was used as the binary dependant variable, where non-adherence was 
defined as absence of at least 1 antihypertensive in the urine antihypertensive assay. A 
preliminary analysis was carried out which included all basic demographics (age, gender 
ethnicity) and clinically-relevant variables (systolic and diastolic BP, eGFR, BMI, total pill 
burden, number of prescribed antihypertensive drugs and antihypertensive drug classes). 
Variables that were significantly different (p<0.05) between the Adherent and Non-adherent 
groups were included in the regression model. Thus, the final prediction model was adjusted 
for gender, age, systolic and diastolic BP, eGFR, number of prescribed antihypertensive 
drugs, total pill burden, and a binary variable indicating whether a patient was prescribed 
calcium channel blockers and diuretics (Model 1). To check for the sensitivity of the missing 
values, a second model was produced which was adjusted for gender, age, number of 
antihypertensives, calcium channel blocker and diuretic use (Model 2). The models’ 
generalisability was evaluated using receiver operating characteristic (ROC) curve to estimate 
the area under the curve. Nagelkerke pseudo R2 was used to summarise the proportion of 
variation in the dependant variable associated with the predictor or independent variables.  
As this analysis was conducted as part of a clinical audit project, Research Ethics Committee 





Three hundred and twenty-two urine samples from 9 hypertension centres across the UK 
were received for analysis during the timeframe. Nineteen patients were excluded for 
duplicate urine samples received and 3 for missing gender description. Thus, 300 patients 
were included in the analysis: the median age was 59 years, 47% were female and 71% 
Caucasian.  The demographic and clinical characteristics of the patients are shown in Table 1.   
The median number of antihypertensive drugs prescribed was 4; 166 (55.3%) were non-
adherent to prescribed medication with no prescribed drug detected in 60 (20%) of patients. 
Non-adherent patients were younger with a median age of 57 years compared to 66 years in 
the adherent group (p<0.001). There were more females (54% vs. 37%, p<0.001) (Figure 1). 
Non-adherent patients had higher systolic (mean 181 vs. 172 mmHg, p = 0.027) and diastolic 
BP (100 vs 90 mmHg, p<0.001); and they were on higher number of antihypertensive drugs 
(median 4 vs 3, p<0.001, Table 1, Figure 1) and total number of drugs prescribed (median 7 
vs 5, p<0.001, Table 1, Figure 2). They also had higher median eGFR (76 ml/min/m2) 
compared with adherent patients (66 ml/min/m2). More patients in the non-adherent group 
were prescribed calcium channel blockers (87% vs 59%) and diuretics (84% vs 64%) 
compared with the adherent group (Table 2). Figure 3 shows the number of drugs in each 
class of antihypertensive agents prescribed versus number detected on urine testing. Further 
sensitivity analysis suggested that dihydropyridine calcium channel blockers were more 
likely to be associated with non-adherence (66.3% in non-adherent group, 33.7% in adherent 
group, p<0.0001) than the non-dihydropyridine calcium channel blocker, (55.6% in non-
adherent group, 44.4% adherent group, p=1). 
We also conducted an exploratory comparative analysis of demographic and clinical 
correlates of complete non-adherence and partial non-adherence. Those who were completely 
non-adherent were younger (median age 53 vs 58 years, p=0.033) and there were more males 
(54% vs 46%, p=0.003) in the complete non-adherence group. All of the other parameters 
were equally distributed between the groups. 
A logistic regression was performed on 206 patients with complete data on all variables, to 
ascertain the effects of gender, age, systolic and diastolic BP, number of all prescribed 
antihypertensive medications, prescribed diuretics and calcium channel blockers, and total 
number of all medications prescribed on the odds that patients are non-adherent to 
antihypertensive medications (Table 2). The logistic regression model was statistically 
significant, χ2 (d.f. 4) = 80.8, p<0.001, Nagelkerke R-square 43.3%, correctly predicted 
73.3% and the area under the curve for this logistic regression model was 0.79 (CI: 0.74, 
0.84; p<0.001) suggesting a fair level of discrimination. 
In this model (Model 1, n = 206) female gender, total pill burden, higher number of 
antihypertensive drugs and prescription of calcium channel blockers were all associated with 
a higher odds ratio (OR) of non-adherence; whilst increasing age was associated with lower 
OR of non-adherence. Model 2 (n=298, after excluding variables with missing data), 
supported the results (Table 2). Figure 4 shows the probability of non-adherence in each age 
quartile in relation to gender, the number of antihypertensive drugs prescribed and 





This study, using a LC-MS/MS based urine drug assay in 300 patients with apparent TRH 
from nine hypertension centres in the UK, demonstrated that 55% of patients were non-
adherent to their prescribed medications with 20% being completely non-adherent. Younger 
age, female gender, total pill burden, number of antihypertensive drugs prescribed and 
prescription of calcium channel blockers were independently associated with non-adherence. 
Suboptimal adherence or non-adherence is common in all chronic conditions; on average 
around 50% of all prescribed medications for chronic conditions are not taken as prescribed 
[21,22]. The conditions most frequently studied have been HIV/AIDS, tuberculosis, epilepsy, 
psychiatric disorders, asthma, chronic obstructive pulmonary disease, cardiovascular disease 
or cardiovascular risk, hypertension, and diabetes [21,23]. Medication wastage due to non-
adherence places an enormous cost burden on the health care system [24].  
In hypertension, the reported prevalence rate of non-adherence varies between 3 and 65% 
[15-18,25,26]. This wide variation may be related to the method of assessment and the study 
population. Studies that used a direct method of assessment - e.g. drug screening using LC-
MS/MS or directly observed therapy – report a higher prevalence of non-adherence compared 
with those that used an indirect method, e.g. prescription refill rate or patient interview. 
Similarly, studies involving patients with apparent TRH report a much higher prevalence of 
nonadherence compared with studies in unselected cohorts of hypertensive individuals. The 
prevalence rate of 55% in our study is similar to other studies that used urine drug monitoring 
in cohorts of apparent TRH [17,25].   
 
The patient cohort in this study was derived from nine hypertension clinics across the UK. 
The median number of antihypertensive agents prescribed was four, and all of the patients 
had secondary hypertension and white-coat effect excluded before urine drug screening was 
carried out. Therefore this was a group of patients with apparent resistance to 
antihypertensive treatment. Observational cohort or cross-sectional studies from specialist 
hypertension centres form the mainstay of studies describing the prevalence of non-adherence 
among patients with TRH reporting high non-adherence rate (50-65%) using serum or urine 
drug assays  [17,25,26]. On the other hand, population studies using indirect measures of 
adherence in large populations report much lower non-adherence rates [27,28].  
 
A recent systematic review summarized 24 published studies reporting adherence in TRH 
[25]. There was an average of 86 patients from 21 studies, the largest of which included 339 
patients. Pooled mean non-adherence rate was 31.2%, with the highest rates reported in 
studies that used direct methods testing patients’ sera or urine, followed by studies that used 
directly observed therapy (47.9% and 44.6% respectively). The lowest rate of non-adherence 
was found in a study reporting on medication possession ratio at 3.3%. 
 
There were significant differences in demographic and clinical parameters between adherent 
and non-adherent patients in this study. Younger age, female gender, number of 
antihypertensive medications prescribed and the prescription of calcium channel blockers 
were independently associated with antihypertensive drug non-adherence.  These findings are 
consistent with a recently published study of 1348 patients with hypertension from the UK 
and Czech Republic, in which adherence was measured in urine and serum respectively by 
LC-MS/MS. That study found younger age, female gender, the number of antihypertensive 
medications prescribed and prescription of diuretics to be associated with non-adherence [29]. 
However, in the aforementioned study, the number of antihypertensive medications 
prescribed was fewer (median 4 and 3 respectively); and BP readings, the number of all 
medications (hypertensive and non-hypertensive) prescribed, ethnicity, BMI and eGFR were 
not reported. 
 
The association between younger age and medication non-adherence has been observed in 
many chronic conditions including hypertension, diabetes, asthma, heart failure and 
depression [30]. However, the association between age and non-adherence in hypertension is 
variable with younger age [29,31-33], older age [34] or no association reported [35,36]. 
Younger patients with busy working lives may have higher unintentional non-adherence. 
Lifelong treatment for a chronic asymptomatic illness may also be a contributing factor. 
Conversely, older patients, with greater burden or severity of illness, are more motivated to 
adhere, and some may have carers to ensure optimal adherence. Furthermore, these patients 
may represent a survivor cohort effect, implying successful medication-taking behaviour.  
 
Lower medication adherence among women has been observed in various chronic conditions 
[37-39] including hypertension [29,32,34,40] The underlying mechanism for this association 
is unclear, but gender-specific factors may be responsible. Different behavioural attitudes 
have been observed with more men admitting to forgetting or changing the dosage or think 
they have recovered from the condition. More women report filling the prescription but not 
taking the drug, and attribute non-adherence to adverse drug reactions [41]. Whilst sexual 
dysfunction and body mass index of ≥25.0 kg/m2 are associated with non-adherence in 
hypertensive men, dissatisfaction with communication with the healthcare provider and 
depressive symptoms are associated with lower adherence in women [42]. 
 
The most important and novel observation in our study is that non-adherence to 
antihypertensive treatment was independently associated with two separate measures of 
polypharmacy, i.e. the number of prescribed antihypertensives and the total number of 
prescribed medications in a cohort with apparent treatment resistant hypertension. The 
association between polypharmacy and medication non-adherence has been reported in a 
number of chronic conditions; including hypertension, type 2 diabetes, coronary artery 
disease and after discharge from hospital following inpatient admission; and has been shown 
to be associated with poorer outcomes [43-48]. Non-adherence is particularly common 
among community dwelling elderly adults who are on multidrug regimens for several 
comorbid conditions presenting a unique challenge to patients and caregivers, and is a public 
health concern [49,50]. Limited evidence suggests that deprescribing may improve 
medication adherence in this situation [51]. In addition to improving adherence, 
deprescribing helps resolution of adverse drug reactions, increases patient engagement with 
treatment, and reduces medication wastage and cost to the health service [52]. 
 
In hypertensive individuals, simplification of treatment regimen has been shown to improve 
BP control [53]. Indeed, a number of studies in mild to moderate hypertension have 
demonstrated improvement in BP control with single pill fixed-dose combination therapy 
[54-56], supporting the view that pill burden is an important intervention target for improving 
long term medication adherence [40]. This concept has been incorporated into the recent 
European Society of Cardiology – European Hypertension Society (ESC-ESH) Guidelines on 
hypertension [57]. However, the evidence in apparent TRH is scanty. A pilot study of 13 
patients found a single-pill fixed triple drug combination reduced clinic BP by 22.8/13.6 
mmHg and 9.3 mmHg in 24-hr mean arterial BP after 18 weeks [58]. Larger studies are 
required to substantiate this. 
 
Previous findings of a highest risk of nonadherence with diuretics [29,59], when compared to 
other classes of antihypertensives, is not replicated in our logistic regression model. Instead, 
prescription of a calcium channel blocker (mainly dihydropyridine) was predictive of non-
adherence. The reason for this discrepancy is unclear. However, in the metanalysis quoted 
above (59), the authors suggested that their observation of diuretics being the most common 
class of antihypertensive associated with non-adherence could not be generalised to those 
taking ≥1 agent. Moreover, this meta-analysis excluded cross-sectional studies reporting 
adherence at a single point in time, making direct comparison with our results inappropriate. 
A recently published study investigating the contribution of adverse effects on 
antihypertensive medication non-adherence has demonstrated that both hydrochlorothiazide, 
a diuretic, and nifedipine, a dihydropyridine calcium channel blocker, are independently 
associated with non-adherence, attributable to adverse effects [60].  This finding should 
prompt clinicians to assess the impact of adverse effects and pharmacological interactions of 
commonly prescribed antihypertensive agents. 
 
 
Reasons for medication non-adherence are complex and multifactorial. Socio-economic, 
health system-related, therapy-related, condition-related and patient-related factors have been 
implicated [61,62]. Patients’ perception of disease and control, treatment-related beliefs, 
coherence of beliefs from experience with medication, habit strength, and pill burden play 
important roles [355,40]. Longitudinal studies are needed to elucidate the roles of these 
factors in predicting adherence at various stages of the chronic illness trajectory including 
that of hypertension. 
Our study has a number of limitations. This was a retrospective study based on the 
demographic and clinical information provided on the request form for urine drug assay. The 
BP readings used in the analysis were clinic/office BP readings at the point of urine testing; 
ambulatory readings were not taken at the point of sending the urine sample. Medication 
doses were not consistently recorded. Adherence was tested only at a single point of time; no 
conclusion can be drawn on long-term adherence in this cohort. Indeed, adherence testing at a 
single time point may have overestimated adherence as medication adherence is known to 
increase as a clinic visit approaches  - the so called ‘white coat adherence’ [63]. Finally, there 
were some missing data, for which we performed a further logistic regression analysis, 
excluding parameters with missing values, which supported the results of the main model.  
The strengths of the study are that the patient sample was drawn from nine hypertension 
centres across the UK and the urine tests were carried out at a single toxicological laboratory 
using a clinically validated, sensitive and specific LC-MS/MS assay. The patient cohort had 
ethnicity composition reflecting the current British urban population. They had uncontrolled 
hypertension and were prescribed a median of 4 antihypertensive drugs each. All patients had 
whitecoat effect and secondary hypertension excluded. To our knowledge, this is the largest 
reported TRH population to have direct testing for adherence to medication. We believe the 
results of this study are generalizable to the apparent TRH population in the UK.  
In conclusion, this study adds to the evidence base suggesting non-adherence to prescribed 
medications is a major cause of apparent resistance to treatment in hypertensive individuals. 
Prospective longitudinal studies are needed to confirm this. This study also identifies a 
number of risk factors for non-adherence in this population, which may help to identify 
patients at risk of medication non-adherence. Of these, pill burden is a modifiable risk factor, 
which provides an intervention target to improve long-term BP control.    
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Table 1: Demography and clinical parameters  
 % missing 
data 
All patients Adherent Non-Adherent p 
No of Patients (%) 0 300 134 (44.7) 166 (55.3) - 
Female (%) 0 141 (46.8) 52 (36.9) 89 (63.1) 0.004 
Age (years) 0 59 
(49 – 70) 
66 
(55 – 74) 
57 
(48 - 64) 
<0.001 
Non-Caucasian (%) 26 65 (29.3) 28 (43.1) 37 (56.9) 0.721 
Antihypertensive drugs 
prescribed 
0 4 (3 – 5) 3 (2 – 4) 4 (3 – 5) <0.001 
CCB 0 223 (74.3) 79 (59.0) 144 (86.7) <0.001 
RASi 0 255 (85.0) 108 (80.6) 147 (88.6) 0.055 
Diuretic 0 226 (75.3) 86 (64.2) 140 (84.3) <0.001 
Beta blocker 0 136 (45.3) 57 (42.5) 79 (47.6) 0.382 
Other 0 184 (61.3) 74 (55.2) 110 (66.3) 0.051 
Total drugs prescribed 24.4 6 (4 – 8) 5 (4 – 7) 7 (5 – 10) <0.001 
Systolic BP (mmHg) 22.7 176 
(160 – 197) 
172 
(158 – 188) 
181 
(161 – 201) 
0.025 
Diastolic BP (mmHg) 22.7 95 
(81 – 110) 
90 
(75 – 105) 
100 







(55 – 86) 
66 
(51 – 79) 
76 






(28.4 – 35.5) 
31.0 
(28.8 – 36.0) 
31.6 
(27.8 – 34.9) 
0.436 
All continuous variables reported as median (IQR). All count variables presented as n (%). 
CCB – calcium channel blocker, RASi – renin angiotensin system inhibitor, BP – blood 
pressure (clinic), eGFR – estimated glomerular filtration rate, BMI – body mass index. 
 
  
Figure 1: Number of antihypertensive drugs prescribed in relation to adherence status 




Box-and-whisker plot to illustrate differences in antihypertensive medications prescribed 
























Box-and-whisker plot to illustrate differences in all drugs prescribed (median and IQR, 
p<0.001). 
  
Table 2: Factors associated with non-adherence to antihypertensive medications 
 
 Model 1 (n = 206)  Model 2 (n = 300) 
Variables Odds ratio 95% CI p  Odds ratio 95% CI p 
Age  0.97 0.94, 1.00 0.082  0.96 0.94, 0.98 <0.001 




1.69 1.11, 2.58 0.015  1.74 1.32, 2.29 <0.001 
CCB 3.51 1.51, 8.16 0.004  2.66 1.37, 5.19 0.004 
Diuretic 0.79 0.30, 2.09 0.643  1.56 0.75, 3.27 0.234 
Total medication 1.18 1.01, 1.37 0.032  
Systolic BP 1.00 0.99, 1.02 0.761  
Diastolic BP 1.02 1.00, 1.05 0.048  
eGFR 1.013 0.99, 1.03 0.112  
 
Binary logistic regression analysis of factors associated with non-adherence to antihypertensive 
medications adjusted for age, gender, clinic systolic blood pressure (BP) and clinic diastolic blood 
pressure, estimated glomerular filtration rate (eGFR), number of antihypertensive drugs prescribed, 
prescriptions of calcium channel blocker (CCB) and diuretic, and total number of medications 
(antihypertensive and other medications) prescribed,  
  
Figure 3: Graphical illustration of the number of medications in each antihypertensive class 





Calcium channel blockers: Amlodipine, Nifedipine, Felodipine, Diltiazem, Verapamil 
Renin Angiotnsin System Inhibitors: Lisinopril, Perindopril, Ramipril, Losartan, 
Irbesartan, Candesartan, Enalapril 
Diuretics: Indapamide, Bendroflumethiazide, Hydrochlorothiazide, Furosemide, 
Spironolactone 
Beta blockers: Atenolol, Bisoprolol, Labetalol, Metoprolol 












Diuretics Beta blockers Others
Prescribed 223 263 295 136 216




























Number of antihypertensives prescribed and detected 
according to class
 
Figure 4: Probability of non-adherence by gender and prescription of calcium channel 
blocker in different age quartiles. 
 
 
 
 
 
 
 
 
 
 
 
 
